AC-262,536

AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.[1]

AC-262,536

Identifiers
IUPAC name 4-[(1R,3S,5S)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl]naphthalene-1-carbonitrile
CAS Number	870888-46-3 871032-12-1 (exo form)
ChemSpider	31129035
UNII	U8VS41J5O6
ChEMBL	ChEMBL3084525
Chemical and physical data
Formula	C18H18N2O
Molar mass	278.355 g·mol^−1
3D model (JSmol)	Interactive image
SMILES OC1C[C@@H]2CC[C@H](C1)N2c3ccc(C#N)c4ccccc34
InChI InChI=1S/C18H18N2O/c19-11-12-5-8-18(17-4-2-1-3-16(12)17)20-13-6-7-14(20)10-15(21)9-13/h1-5,8,13-15,21H,6-7,9-10H2/t13-,14+,15+ Key:ATKWLNSCJYLXPF-FICVDOATSA-N
(verify)

References

1. Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, et al. (March 2008). "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". The Journal of Steroid Biochemistry and Molecular Biology. 109 (1–2): 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613. S2CID 25172405.